text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 366017-09-6 | Product Number: M3058

Mubritinib


Purity: >98.0%(HPLC)
Synonyms:
  • (E)-4-[[4-[4-(1H-1,2,3-Triazol-1-yl)butyl]phenoxy]methyl]-2-[4-(trifluoromethyl)styryl]oxazole
  • TAK 165
Product Documents:
25MG
¥22,800
1   1   1  
100MG
¥68,200
6   1   Contact Us
* Available Stock: Prompt shipment (for products) in Saitama/Hyogo warehouse. Stock In Other WH: Shipment in about 2-3 Business Days from Saitama warehouse. Please contact us if you need further information.
* The displayed price is the unit price and does not include consumption tax. The unit prices displayed are the latest and are subject to change without notice.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Product Number M3058
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__2__5H__2__3F__3N__4O__2 = 468.48 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Heat Sensitive
Packaging and Container 25MG-Glass Bottle with Plastic Insert (View image)
CAS RN 366017-09-6
Reaxys Registry Number 13498857
PubChem Substance ID 354335238
MDL Number

MFCD09954135

Specifications
Appearance White to Gray to Brown powder to crystal
Purity(HPLC) min. 98.0 area%
Melting point 158.0 to 162.0 °C
NMR confirm to structure
Properties (reference)
Melting Point 160 °C
GHS
Related Laws:
Transport Information:
Application
ヒト上皮成長因子受容体2 (HER2) チロシンキナーゼ阻害剤,ムブリチニブ

Small-molecule protein kinase inhibitors are widely used to elucidate cellular signaling pathways. Mubritinib (TAK 165) is a selective inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Reportedly, mubritinib specifically inhibits HER2 tyrosine kinase IC50 6 nmol/L and do not inhibit other types of tyrosine kinase up to 25,000 nmol/L.1) Several reports suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen-independent prostate cancer. However, the clinical development program for mubritinib as an anti-cancer drug was discontinued. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.